Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc.
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Extensive Stage Small Cell Lung Cancer | Recruiting | Phase 1 | 2026-09-25 | NCT07037758 | |
| AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Advanced Melanoma; Advanced Melanoma and Normal or Impaired | Recruiting | Phase 1 | 2026-06-16 | NCT07027488 | |
| A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 | 2025-09-10 | NCT05653882 |